No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Sector
Biotechnology
Esperion Therapeutics, Inc. operates as a pharmaceutical company primarily focused on developing and commercializing medications designed to manage elevated low-density lipoprotein (LDL) cholesterol levels in patients. Its flagship pharmaceutical products include NEXLETOL (bempedoic acid) and NEXLIZET (a combination of bempedoic acid and ezetimibe) in tablet form. These treatments are prescribed for individuals suffering from atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH). Additionally, Esperion has established strategic licensing and collaborative partnerships with Daiichi Sankyo Europe GmbH and Serometrix to obtain rights to an oral, small molecule PCSK9 inhibitor program. The company was founded in 2008 and its principal offices are located in Ann Arbor, Michigan.
www.esperion.comNo one on the platform currently holds 0IIM.L.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,620,100 | $4.4M |
No one on the platform has traded 0IIM.L yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 21.3% | 12.1% | ||||
| Profit Margin % | -5.6% | -170.7% | ||||
| Free Cash Flow Margin % | -3.2% | -139.0% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $388M | -3.6% | $-0.04 | $-0.05–$-0.03 | — | 1 |
| 2027 | $449M | +15.8% | $0.27 | $0.19–$0.34 | — | 1 |
| 2028 | $505M | +12.4% | $0.43 | $0.30–$0.55 | — | 1 |
| 2029 | $659M | +30.6% | $0.51 | $0.36–$0.65 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-05-08 | $-0.04 | $-0.10 | -169.3% |
| 2026-03-10 | $0.24 | $0.22 | -9.6% |
| 2025-11-06 | $-0.08 | $-0.16 | -104.3% |
| 2025-08-05 | $-0.15 | $-0.02 | +83.4% |
| 2025-05-06 | $-0.15 | $-0.21 | -35.7% |
| 2025-03-04 | $-0.15 | $-0.11 | +26.6% |
| 2024-11-07 | $-0.18 | $-0.15 | +14.4% |
| 2024-08-12 | $-0.17 |
| $-0.33 |
| -90.5% |
| +2.66% |
| $367M |
| — |
| 0IV3.LGeron Corporation | $1.31 | +0.49% | $879M | — |
| 0J4V.LHeron Therapeutics, Inc. | $0.32 | +1.22% | $57M | — |
Source: Financial Modeling Prep · peers by sector/industry